Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement.
Wu CT, Targher G, Byrne CD, Younossi ZM, Armstrong MJ, Luu HN, Lesmana CRA, Rustgi VK, Thomas JA, Okabayashi K, Lee JWJ, El-Serag HB, Kim W, Zhang HJ, Lonardo A, Souza M, George ES, Yang W, Yilmaz Y, Papatheodoridis G, Sookoian S, Romero-Gómez M, Sebastiani G, Schattenberg JM, El-Kassas M, Chan WK, Ocama P, Lupșor-Platon M, Perera N, Alswat K, Méndez-Sánchez N, Wong VW, Chai J, Tilg H, Sung JJ, Zheng MH.
Wu CT, et al.
Gut. 2026 Sep 7;75(10):2009-2018. doi: 10.1136/gutjnl-2025-337374.
Gut. 2026.
PMID: 41770836
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiological evidence indicates that MASLD is associated with an increased risk of developing colorectal cancer (CRC). ...CONCLUSION: The exp …
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiolog …